心脏骤停患者糖皮质激素治疗的疗效与安全性:随机对照试验的Meta分析
该Meta分析检索PubMed、Embase、Cochrane Library、Web of Science和CNKI数据库,纳入11项比较心脏骤停期间糖皮质激素与安慰剂的随机对照试验,共2273例患者。结果显示糖皮质激素治疗与持续ROSC率升高显著相关(OR 2.05,95%CI 1.24–3.37,P<0.01),但良好神经功能预后(OR 1.13,95%CI 0.81–1.58,P=0.49)和出院总生存率(OR 1.29,95%CI 0.74–2.26,P=0.38)无显著获益。亚组分析中,甲泼尼龙剂量超过100 mg的患者生存率和ROSC显著升高。不良事件无显著差异。作者认为大剂量糖皮质激素(甲泼尼龙超过100 mg)与更好的出院总生存率和ROSC结局相关,但该治疗对出院时良好神经功能预后的获益或危害尚不确定。
要点
- 心脏骤停期间糖皮质激素治疗与持续ROSC率升高显著相关(OR 2.05,95%CI 1.24–3.37,P<0.01)。
- 糖皮质激素对良好神经功能预后无显著获益(OR 1.13,95%CI 0.81–1.58,P=0.49)。
- 糖皮质激素对出院总生存率无显著获益(OR 1.29,95%CI 0.74–2.26,P=0.38)。
- 亚组分析显示甲泼尼龙剂量超过100 mg的患者生存率和ROSC显著升高。
- 不良事件无显著差异;该治疗对出院时良好神经功能预后的获益或危害尚不确定。
适用人群与场景
- 心脏骤停(CA)患者,比较糖皮质激素治疗与安慰剂的随机对照试验人群,共2273例。
研究设计与关键结果
- 研究类型:随机对照试验的Meta分析,纳入11项研究,共2273例患者。
- 持续ROSC:糖皮质激素组较安慰剂组升高,OR 2.05(95%CI 1.24–3.37,P<0.01)。
- 良好神经功能预后:糖皮质激素组与安慰剂组无显著差异,OR 1.13(95%CI 0.81–1.58,P=0.49)。
- 出院总生存率:糖皮质激素组与安慰剂组无显著差异,OR 1.29(95%CI 0.74–2.26,P=0.38)。
- 亚组分析:甲泼尼龙剂量超过100 mg的患者生存率和ROSC显著升高。
- 不良事件:糖皮质激素组与安慰剂组无显著差异。
证据类型、等级与局限
- 证据类型:随机对照试验的Meta分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对心脏骤停患者,糖皮质激素治疗与持续ROSC率升高相关,但良好神经功能预后和出院总生存率无显著获益;作者认为甲泼尼龙剂量超过100 mg与更好的出院总生存率和ROSC结局相关,但该治疗对出院时良好神经功能预后的获益或危害尚不确定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The clinical benefits of steroid therapy during cardiac arrest (CA) are unclear. Several recent clinical trials have shown that administering corticosteroid therapy during CA may improve patient outcomes. The purpose of the present study was to determine whether providing corticosteroids improves outcomes for patients following CA.
METHODS: We searched the PubMed, Embase, Cochrane Library, Web of Science and CNKI databases for randomized controlled trials comparing corticosteroid therapy to placebo during CA.
RESULTS: Eleven relevant studies involving a total of 2273 patients were included in the meta-analysis. The statistical analysis showed that corticosteroid treatment during CA was significantly associated with an increased rate of sustained return of spontaneous circulation (ROSC) (OR: 2.05, 95% CI: 1.24 to 3.37, P < 0.01). Corticosteroid treatment during CA did not show a significant benefit in favorable neurological outcomes (OR: 1.13, 95% CI: 0.81 to 1.58, P = 0.49) or overall survival rate at hospital discharge (OR: 1.29, 95% CI: 0.74 to 2.26, P = 0.38). However, in the subgroup analysis, we found that patients had a significantly increased survival rate and ROSC if the dose of corticosteroid therapy above 100 mg methylprednisolone. The statistical analysis revealed no significant differences in adverse events.
CONCLUSION: High-dose corticosteroid treatment (above 100 mg methylprednisolone) is associated with better overall survival rate at hospital discharge and ROSC outcomes. However, there is uncertainty regarding whether this treatment results in a benefit or harm to the favorable neurological outcomes at hospital discharge.
参考来源
- Zhou FW, Liu C, Li DZ, et al. Efficacy and safety of corticosteroid therapy in patients with cardiac arrest: A meta-analysis of randomized controlled trials. Am J Emerg Med. 2023. PMID: 37939521. doi:10.1016/j.ajem.2023.10.031
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。